GlassScriptPhysician profile
Maya D Srivastava
NPI 1982615100
$1,835,037.87
in general payments reported to CMS, 2019-2025
25 companies · $365K in 2025
The $365K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259K · 2020: $69K · 2021: $77K · 2022: $340K · 2023: $345K · 2024: $380K · 2025: $365K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $851K · Travel and Lodging: $214K · Food and Beverage: $17K · Consulting Fee: $8,621 · Education: $85.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $850,714.66 |
| Travel and Lodging | $214,025.23 |
| Food and Beverage | $16,883.36 |
| Consulting Fee | $8,621.25 |
| Education | $85.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $427,268.69 | 2019-2025 | |
| Janssen Biotech, INC. | $339,067.76 | 2021-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $305,142.28 | 2020-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $296,005.26 | 2019-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $215,908.08 | 2019-2025 | Tremfya |
| Abbvie INC. | $193,141.55 | 2019-2025 | Rinvoq, Skyrizi, Ubrelvy |
| Ucb, INC. | $44,164.56 | 2019-2020 | |
| Grifols USA, LLC | $4,511.72 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $4,052.91 | 2021 | |
| Pfizer INC. | $2,418.01 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $2,123.53 | 2020-2021 | |
| Csl Behring | $491.85 | 2019-2024 | Haegarda |
| Astrazeneca Pharmaceuticals LP | $240.03 | 2024-2025 | Fasenra |
| Glaxosmithkline, LLC. | $142.30 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $94.67 | 2025 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $49.49 | 2019 | |
| Celgene Corporation | $42.49 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $38.70 | 2020 | |
| Kaleo, INC. | $32.60 | 2019-2021 | |
| Alfasigma USA, INC. | $20.92 | 2020 | |
| Sandoz INC. | $19.88 | 2023 | Hyrimoz |
| Phadia US INC. | $16.71 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.54 | 2024 | Trulance |
| Biocryst US Sales Co., LLC | $16.08 | 2021 | |
| Shire North American Group INC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Srivastava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.